Literature DB >> 12878439

Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis.

Gerald D Silverberg1, Martha Mayo, Thomas Saul, Edward Rubenstein, Dawn McGuire.   

Abstract

There is evidence that production and turnover of CSF help to clear toxic molecules such as amyloid-beta peptide (Abeta) from the interstitial-fluid space of the brain to the bloodstream. Two changes in CSF circulatory physiology have been noted as part of ageing: first, a trend towards lower CSF production, hence a decrease in CSF turnover; and second, greater resistance to CSF outflow. Our hypothesis is that, all else being equal, the initially dominant physiological change determines whether CSF circulatory failure manifests as Alzheimer's disease (AD) or as normal-pressure hydrocephalus (NPH). If CSF production failure predominates, AD develops. However, if resistance to CSF outflow predominates, NPH results. Once either disease process takes hold, the risk of the other disorder may rise. In AD, increased deposition of Abeta in the meninges leads to greater resistance to CSF outflow. In NPH, raised CSF pressure causes lower CSF production and less clearance of Abeta. The disorders may ultimately converge in vulnerable individuals, resulting in a hybrid as has been observed in several clinical series. We postulate a new nosological entity of CSF circulatory failure, with features of AD and NPH. NPH-AD may cover an important subset of patients who carry the diagnosis of either AD or NPH.

Entities:  

Mesh:

Year:  2003        PMID: 12878439     DOI: 10.1016/s1474-4422(03)00487-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  120 in total

Review 1.  [Arterial hypertension and dementia].

Authors:  R Scheid; H Voigt
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

2.  Cerebrospinal fluid dynamics in the human cranial subarachnoid space: an overlooked mediator of cerebral disease. II. In vitro arachnoid outflow model.

Authors:  David W Holman; Vartan Kurtcuoglu; Deborah M Grzybowski
Journal:  J R Soc Interface       Date:  2010-03-24       Impact factor: 4.118

3.  Cerebrospinal fluid dynamics in the human cranial subarachnoid space: an overlooked mediator of cerebral disease. I. Computational model.

Authors:  Sumeet Gupta; Michaela Soellinger; Deborah M Grzybowski; Peter Boesiger; John Biddiscombe; Dimos Poulikakos; Vartan Kurtcuoglu
Journal:  J R Soc Interface       Date:  2010-03-17       Impact factor: 4.118

4.  High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity.

Authors:  Hisham Qosa; Loqman A Mohamed; Sweilem B Al Rihani; Yazan S Batarseh; Quoc-Viet Duong; Jeffrey N Keller; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

Review 5.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

6.  Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting.

Authors:  R Bech-Azeddine; P Høgh; M Juhler; F Gjerris; G Waldemar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

7.  [Idiopathic normal-pressure hydrocephalus. Flow measurement of cerebrospinal fluid using phase contrast MRI and its diagnostics importance].

Authors:  F T Al-Zain; G Rademacher; J Lemcke; J Mutze; U Meier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

8.  Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.

Authors:  Tommaso Schirinzi; Giulia Di Lazzaro; Giulia Maria Sancesario; Vito Luigi Colona; Eugenia Scaricamazza; Nicola Biagio Mercuri; Alessandro Martorana; Giuseppe Sancesario
Journal:  J Neural Transm (Vienna)       Date:  2017-09-02       Impact factor: 3.575

Review 9.  Gender differences in Parkinson's disease: focus on plasma α-synuclein.

Authors:  Giovanni Caranci; Paola Piscopo; Roberto Rivabene; Anna Traficante; Barbara Riozzi; Anna Elisa Castellano; Stefano Ruggieri; Nicola Vanacore; Annamaria Confaloni
Journal:  J Neural Transm (Vienna)       Date:  2013-01-18       Impact factor: 3.575

10.  Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Authors:  Hisham Qosa; Bilal S Abuasal; Ignacio A Romero; Babette Weksler; Pierre-Oliver Couraud; Jeffrey N Keller; Amal Kaddoumi
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.